Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong · Delayed Price · Currency is HKD 43.32
+1.62 (3.88%)
Nov 10, 2026, 4:08 PM HKT
HKG:2315 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 35,523 | 23,585 | 3,395 | 4,785 | 10,245 | - | |
Market Cap Growth | 217.65% | 594.71% | -29.05% | -53.29% | - | - |
Enterprise Value | 35,319 | 23,859 | 3,562 | 4,682 | 10,003 | - |
Last Close Price | 43.32 | 35.30 | 8.50 | 11.98 | 25.65 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 43.83 | 122.37 | 95.11 | - | - | - |
Forward PE | 42.88 | 49.96 | - | - | - | - |
PS Ratio | 16.50 | 15.37 | 3.25 | 6.06 | 16.97 | - |
PB Ratio | 12.15 | 9.72 | 3.80 | 5.50 | 7.87 | - |
P/TBV Ratio | 12.42 | 9.81 | 3.92 | 5.73 | 8.12 | - |
P/FCF Ratio | 192.58 | 75.04 | 18.32 | - | - | - |
P/OCF Ratio | 57.37 | 57.24 | 15.10 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 16.40 | 15.55 | 3.41 | 5.93 | 16.57 | - |
EV/EBITDA Ratio | 48.11 | 52.84 | 11.63 | - | - | - |
EV/EBIT Ratio | 65.85 | 76.94 | 22.29 | - | - | - |
EV/FCF Ratio | 191.48 | 75.91 | 19.23 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.32 | 0.27 | 0.68 | 0.69 | 0.36 | 0.07 |
Debt / EBITDA Ratio | 1.25 | 1.34 | 1.81 | - | - | - |
Debt / FCF Ratio | 5.14 | 2.07 | 3.28 | - | - | - |
Net Debt / Equity Ratio | -0.07 | -0.46 | 0.19 | 0.14 | -0.20 | -0.39 |
Net Debt / EBITDA Ratio | -0.29 | -2.49 | 0.55 | -0.71 | 0.49 | 1.16 |
Net Debt / FCF Ratio | -1.14 | -3.58 | 0.91 | -0.54 | 0.42 | 0.86 |
Asset Turnover | 0.59 | 0.45 | 0.40 | 0.27 | 0.21 | 0.15 |
Inventory Turnover | 1.73 | 26.17 | 26.80 | 12.25 | 6.09 | 6.11 |
Quick Ratio | 2.30 | 2.05 | 1.21 | 1.01 | 1.25 | 1.55 |
Current Ratio | 2.95 | 2.31 | 1.53 | 1.25 | 1.52 | 1.96 |
Return on Equity (ROE) | 21.35% | 11.48% | 4.12% | -39.45% | -50.12% | -40.27% |
Return on Assets (ROA) | 9.65% | 5.67% | 3.86% | -6.94% | -14.81% | -14.02% |
Return on Invested Capital (ROIC) | 21.18% | 23.71% | 12.36% | -31.99% | -71.53% | -76.89% |
Return on Capital Employed (ROCE) | 15.00% | 10.00% | 8.00% | -15.60% | -27.60% | -28.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.28% | 0.82% | 1.05% | -8.82% | -6.64% | - |
FCF Yield | 0.52% | 1.33% | 5.46% | -4.68% | -6.00% | - |
Buyback Yield / Dilution | -11.46% | -0.52% | 0.08% | -4.54% | -5.13% | -180.82% |